Romosozumab, a recently developed sclerostin inhibitor, stimulates bone formation and inhibits bone resorption, thereby markedly increasing bone mass and reducing fracture risk. But will a red flag regarding possible adverse cardiovascular events derail this promising new drug for osteoporosis?
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Khosla, S. & Hofbauer, L. C. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. http://dx.doi.org/10.1016/s2213-8587(17)30188-2 (2017).
Brunkow, M. E. et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577–589 (2001).
Khosla, S., Westendorf, J. J. & Oursler, M. J. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 118, 421–428 (2008).
Li, X. et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578–588 (2009).
McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412–420 (2014).
Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532–1543 (2016).
Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1708322 (2017).
Rosen, C. J. Romosozumab — promising or practice changing? N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMe1711298 (2017).
Tanko, L. B. et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J. Bone. Miner. Res. 20, 1912–1920 (2005).
Gay, A. & Towler, D. A. Wnt signaling in cardiovascular disease: opportunities and challenges. Curr. Opin. Lipidol. 28, 387–396 (2017).
The author's work is supported by NIH grants AG004875, AG048792 and AR027065. In addition, the author greatly appreciates the critical review of this article by M. Drake and J. Farr.
The author declares no competing financial interests.
About this article
Cite this article
Khosla, S. Romosozumab — on track or derailed?. Nat Rev Endocrinol 13, 697–698 (2017). https://doi.org/10.1038/nrendo.2017.136
International Journal of Molecular Sciences (2020)
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis
Clinical Obstetrics & Gynecology (2020)
Arteriosclerosis, Thrombosis, and Vascular Biology (2019)
Journal of Clinical Periodontology (2019)